FDA Approval: LLS Applauds New Advance for Acute Lymphoblastic Leukemia

 From the Leukemia & Lymphoma Society

RYE BROOK, N.Y. (August 17, 2017) – The Leukemia & Lymphoma Society (LLS) applauds today’s approval by the U.S. Food and Drug Administration (FDA) of inotuzumab ozogamicin (Besponsa®) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Post by Barb Flynn

Leave a Reply

Your email address will not be published. Required fields are marked *